ArticleEULAR rheumatology open2025
The association between ethnicity, socioeconomic position and outcomes following initiation of methotrexate in juvenile idiopathic arthritis.
Article in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This analysis investigates changes in disease activity and treatment persistence following initiation of methotrexate in children and young people with juvenile idiopathic arthritis (JIA), by ethnic group and socioeconomic position. Methods: Patients registered in the UK JIA Biologics Register starting methotrexate were included. Outcomes included a change in disease activity between treatment commencement and 6 months. Adjusted multivariable linear regression was used to assess the association between ethnicity or socioeconomic position. Treatment persistence was analysed using Kaplan-Meier estimates. Cox proportional hazards models were used to compare drug persistence between groups. Results: A total of 993 patients were included; 69% women, 88% White ethnic group (2% Mixed, 8% Asian, and 2% Black), and 24% in the most deprived socioeconomic group. Disease activity improved after 6 months for most children. There was no evidence that improvement differed by ethnicity or socioeconomic position.The proportion of patients remaining on methotrexate at 12 months varied by ethnic group (61% of children with White ethnicity, 64% Asian, 65% Black, and 67% of children with Mixed ethnicity). The likelihood of stopping methotrexate over the 12-month period was similar between ethnicities and socioeconomic groups. Conclusions: Improvements in disease activity in the first 6 months following initiation of methotrexate in children and young people with JIA are similar between ethnic groups and independent of socioeconomic position. Although small sample sizes limit robust conclusions, further research to understand whether differences are seen following initiation of other therapies for JIA and the drivers of these differences is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.